Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus

Safinamide is a highly selective, reversible MAO B-inhibitor recently marketed in European and North American countries. To better define clinical indications regarding motor and non-motor symptoms, targeted population and safety of this compound, ten movement disorders specialists, experts in their...

Descripción completa

Detalles Bibliográficos
Autores principales: Stocchi, Fabrizio, Antonini, Angelo, Berg, Daniela, Bergmans, Bruno, Jost, Wolfgang, Katzenschlager, Regina, Kulisevsky, Jaime, Odin, Per, Valldeoriola, Francesc, Ray Chaudhuri, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861053/
https://www.ncbi.nlm.nih.gov/pubmed/35190544
http://dx.doi.org/10.1038/s41531-022-00277-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861053/
https://www.ncbi.nlm.nih.gov/pubmed/35190544
http://dx.doi.org/10.1038/s41531-022-00277-z

Ejemplares similares